FOLD Amicus Therapeutics Inc
Price (delayed)
$7.1
Market cap
$2.13B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.18
Enterprise value
$2.36B
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics
Highlights
The EPS has soared by 65% YoY and by 47% from the previous quarter
The net income has soared by 63% YoY and by 46% QoQ
Key stats
What are the main financial stats of FOLD
Market
Valuations
Earnings
Shares outstanding
300.12M
Market cap
$2.13B
Enterprise value
$2.36B
Price to earnings (P/E)
N/A
Price to book (P/B)
10.93
Price to sales (P/S)
4.09
EV/EBIT
113.27
EV/EBITDA
80.33
EV/Sales
4.47
Revenue
$528.3M
Gross profit
$475.35M
Operating income
$24.88M
Net income
-$56.11M
EBIT
$20.84M
EBITDA
$29.39M
Free cash flow
-$37.44M
Per share
Balance sheet
Liquidity
EPS
-$0.18
EPS diluted
-$0.18
Free cash flow per share
-$0.12
Book value per share
$0.65
Revenue per share
$1.74
TBVPS
$1.87
Total assets
$785.03M
Total liabilities
$590.99M
Debt
$443.64M
Equity
$194.05M
Working capital
$356.03M
Debt to equity
2.29
Current ratio
3.39
Quick ratio
2.36
Net debt/EBITDA
7.82
Margins
Efficiency
Dividend
EBITDA margin
5.6%
Gross margin
90%
Net margin
-10.6%
Operating margin
4.7%
Return on assets
-7.4%
Return on equity
-35.3%
Return on invested capital
3.4%
Return on capital employed
3.3%
Return on sales
3.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FOLD stock price
How has the Amicus Therapeutics stock price performed over time
Intraday
2.75%
1 week
5.97%
1 month
-21.15%
1 year
-33.71%
YTD
-24.63%
QTD
-12.99%
Financial performance
How have Amicus Therapeutics's revenue and profit performed over time
Revenue
$528.3M
Gross profit
$475.35M
Operating income
$24.88M
Net income
-$56.11M
Gross margin
90%
Net margin
-10.6%
Amicus Therapeutics's operating income has surged by 133% YoY
The operating margin has soared by 125% YoY
FOLD's net margin has surged by 72% year-on-year and by 50% since the previous quarter
The net income has soared by 63% YoY and by 46% QoQ
Growth
What is Amicus Therapeutics's growth rate over time
Valuation
What is Amicus Therapeutics stock price valuation
P/E
N/A
P/B
10.93
P/S
4.09
EV/EBIT
113.27
EV/EBITDA
80.33
EV/Sales
4.47
The EPS has soared by 65% YoY and by 47% from the previous quarter
The P/B is 46% below the last 4 quarters average of 20.3 and 42% below the 5-year quarterly average of 18.8
The equity has grown by 21% YoY and by 9% from the previous quarter
FOLD's price to sales (P/S) is 61% lower than its 5-year quarterly average of 10.4 and 40% lower than its last 4 quarters average of 6.8
FOLD's revenue is up by 32% year-on-year and by 7% since the previous quarter
Efficiency
How efficient is Amicus Therapeutics business performance
The ROIC has soared by 120% YoY
The ROS has soared by 116% YoY
Amicus Therapeutics's return on equity has surged by 70% YoY and by 49% QoQ
FOLD's ROA has soared by 64% YoY and by 46% from the previous quarter
Dividends
What is FOLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FOLD.
Financial health
How did Amicus Therapeutics financials performed over time
FOLD's total assets is 33% greater than its total liabilities
FOLD's current ratio is up by 18% year-on-year and by 8% since the previous quarter
Amicus Therapeutics's quick ratio has increased by 7% from the previous quarter and by 6% YoY
FOLD's debt is 129% greater than its equity
The equity has grown by 21% YoY and by 9% from the previous quarter
FOLD's debt to equity is down by 18% YoY and by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.